<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941821</url>
  </required_header>
  <id_info>
    <org_study_id>G/P RWS China</org_study_id>
    <nct_id>NCT03941821</nct_id>
  </id_info>
  <brief_title>Glecaprevir/Pibrentasvir Real-world Study in China</brief_title>
  <official_title>The Efficacy, Safety and Long-term Prognosis of Glecaprevir/Pibrentasvir in the Treatment of Chronic Hepatitis C Patients in China--A Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, adverse effect, short - and long-term outcomes of
      Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or
      compensatory cirrhosis)in China through a real-world study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, prospective, real-world study, aiming to investigate the use of
      Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and
      evaluate its effectiveness and safety across a heterogeneous population in
      China.Approximately 800 patients will take part in this study, 20 sites will be included
      which distribute in China's major cities, thus each site will enroll 40 patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SVR 12</measure>
    <time_frame>12 weeks after Glecaprevir/Pibrentasvir treatments</time_frame>
    <description>The effectiveness of Glecaprevir/Pibrentasvir treatments and SVR rate 12 weeks after Glecaprevir/Pibrentasvir treatments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression of Chronic liver disease</measure>
    <time_frame>5 years after Glecaprevir/Pibrentasvir treatments</time_frame>
    <description>Incidence of liver disease progression (such as cirrhosis, decompensation of liver function, liver cancer, liver transplantation, or liver related death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>long term outcome</measure>
    <time_frame>5 years</time_frame>
    <description>Assess the duration of the virologic response (5 years) in CHC patients with daas-based regimens who have achieved a sustained virologic response (svr12/24) at 12 or 24 weeks after the end of treatment and analyze the factors influencing the recurrence of HCV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the impact of DAAs treatment on health-related quality of life (HRQOL) and health status of CHC patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>G/P treatment</arm_group_label>
    <description>Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment</description>
    <arm_group_label>G/P treatment</arm_group_label>
    <other_name>Mavyret</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, urine and whole blood will be restored in central lab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C who will received Glecaprevir/Pibrentasvir treatment and
        meet the inclusion and exclusion criteria above
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  Meet the standard of Glecaprevir/Pibrentasvir treatment

        Exclusion Criteria:

          -  Patients have contraindications to Glecaprevir/Pibrentasvir

          -  Pregnancy or lactation

          -  Malignancy

          -  Decompensatory cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Ning, PHD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College HUST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Qin, PHD,MD</last_name>
    <phone>+8602783662391</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guang Chen, Physcian</last_name>
    <phone>+8602783663604</phone>
    <email>widechain@163.com</email>
  </overall_contact_backup>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

